FDA To Complete Prilosec, Nexium Safety Review In November, CDER Says

FDA is continuing to investigate safety data on AstraZeneca's proton pump inhibitors Prilosec and Nexium (omeprazole and esomeprazole, respecttively), but announced a preliminary conclusion the drugs do not present an increased cardiovascular risk